Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose. Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.
Acetylcysteine was granted FDA approval on 14 September 1963.
Acetylcysteine is indicated for mucolytic therapy and in the management of acetaminophen overdose.
Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of
Div. Endocrinology, Diabetology and Metabolism - University of Turin, Turin, TO, Italy
Michael E. DeBakey VA Medical Center, Houston, Texas, United States
Aberdeen Royal Infirmary, Aberdeen, United Kingdom
Royal Infirmary of Edinburgh, Edinburgh, United Kingdom
Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom
Boston Medical Center, Boston, Massachusetts, United States
Lindner Center of HOPE, Mason, Ohio, United States
Medical University of South Carolina, Charleston, South Carolina, United States
CHU de Nice, NICE cedex 01, Alpes Maritimes, France
University Hospital Ghent, Ghent, Belgium
University of Sao Paulo General Hospital Kidney Transplant Unit, Sao Paulo, Brazil
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.